Form 4: Sutro Biopharma COO Jane Chung Reports Stock Option and RSU Grants

Jane Chung, COO of Sutro Biopharma, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Summary

• Jane Chung, the President and COO of Sutro Biopharma, filed a Form 4 with the SEC on March 7, 2024.
• The filing reports the grant of stock options and restricted stock units (RSUs).
• Chung was granted options to purchase 50,000 shares of Sutro Biopharma common stock at an exercise price of $4.54 on March 5, 2024.
• These options vest monthly starting April 1, 2024, and will be fully vested by March 1, 2028, contingent upon continued service.
• Chung also received 100,000 RSUs on March 5, 2024, which will vest annually beginning March 1, 2025, also subject to continued service.
• Each RSU represents the right to receive one share of Sutro Biopharma common stock upon settlement.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and generally viewed as a positive sign of aligning management interests with shareholders. There are no explicitly negative aspects in the filing.

Positives

• The granting of stock options and RSUs to the COO aligns her interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options and RSUs are common forms of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice in the biotech industry for executive compensation.
• Vesting schedules, like the monthly vesting for options and annual vesting for RSUs, are typical to incentivize long-term commitment.
• The specific amounts of options and RSUs granted would need to be compared to peer companies of similar size and stage of development to assess relative generosity.

Stakeholder Impact

• Shareholders may view the grants as a positive sign of incentivizing management.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates